First Time Loading...

Standard BioTools Inc
NASDAQ:LAB

Watchlist Manager
Standard BioTools Inc Logo
Standard BioTools Inc
NASDAQ:LAB
Watchlist
Price: 2.36 USD -2.48%
Updated: Apr 26, 2024

Intrinsic Value

LAB's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. [ Read More ]

The intrinsic value of one LAB stock under the Base Case scenario is 3.84 USD. Compared to the current market price of 2.36 USD, Standard BioTools Inc is Undervalued by 39%.

Key Points:
LAB Intrinsic Value
Base Case
3.84 USD
Undervaluation 39%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Standard BioTools Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling LAB stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Standard BioTools Inc

Provide an overview of the primary business activities
of Standard BioTools Inc.

What unique competitive advantages
does Standard BioTools Inc hold over its rivals?

What risks and challenges
does Standard BioTools Inc face in the near future?

Has there been any significant insider trading activity
in Standard BioTools Inc recently?

Summarize the latest earnings call
of Standard BioTools Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Standard BioTools Inc.

Provide P/S
for Standard BioTools Inc.

Provide P/E
for Standard BioTools Inc.

Provide P/OCF
for Standard BioTools Inc.

Provide P/FCFE
for Standard BioTools Inc.

Provide P/B
for Standard BioTools Inc.

Provide EV/S
for Standard BioTools Inc.

Provide EV/GP
for Standard BioTools Inc.

Provide EV/EBITDA
for Standard BioTools Inc.

Provide EV/EBIT
for Standard BioTools Inc.

Provide EV/OCF
for Standard BioTools Inc.

Provide EV/FCFF
for Standard BioTools Inc.

Provide EV/IC
for Standard BioTools Inc.

Show me price targets
for Standard BioTools Inc made by professional analysts.

What are the Revenue projections
for Standard BioTools Inc?

How accurate were the past Revenue estimates
for Standard BioTools Inc?

What are the Net Income projections
for Standard BioTools Inc?

How accurate were the past Net Income estimates
for Standard BioTools Inc?

What are the EPS projections
for Standard BioTools Inc?

How accurate were the past EPS estimates
for Standard BioTools Inc?

What are the EBIT projections
for Standard BioTools Inc?

How accurate were the past EBIT estimates
for Standard BioTools Inc?

Compare the revenue forecasts
for Standard BioTools Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Standard BioTools Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Standard BioTools Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Standard BioTools Inc compared to its peers.

Compare the P/E ratios
of Standard BioTools Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Standard BioTools Inc with its peers.

Analyze the financial leverage
of Standard BioTools Inc compared to its main competitors.

Show all profitability ratios
for Standard BioTools Inc.

Provide ROE
for Standard BioTools Inc.

Provide ROA
for Standard BioTools Inc.

Provide ROIC
for Standard BioTools Inc.

Provide ROCE
for Standard BioTools Inc.

Provide Gross Margin
for Standard BioTools Inc.

Provide Operating Margin
for Standard BioTools Inc.

Provide Net Margin
for Standard BioTools Inc.

Provide FCF Margin
for Standard BioTools Inc.

Show all solvency ratios
for Standard BioTools Inc.

Provide D/E Ratio
for Standard BioTools Inc.

Provide D/A Ratio
for Standard BioTools Inc.

Provide Interest Coverage Ratio
for Standard BioTools Inc.

Provide Altman Z-Score Ratio
for Standard BioTools Inc.

Provide Quick Ratio
for Standard BioTools Inc.

Provide Current Ratio
for Standard BioTools Inc.

Provide Cash Ratio
for Standard BioTools Inc.

What is the historical Revenue growth
over the last 5 years for Standard BioTools Inc?

What is the historical Net Income growth
over the last 5 years for Standard BioTools Inc?

What is the current Free Cash Flow
of Standard BioTools Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Standard BioTools Inc.

Financials

Balance Sheet Decomposition
Standard BioTools Inc

Current Assets 158.2m
Cash & Short-Term Investments 114.9m
Receivables 19.7m
Other Current Assets 23.7m
Non-Current Assets 164.9m
PP&E 54.9m
Intangibles 107.7m
Other Non-Current Assets 2.3m
Current Liabilities 109.3m
Accounts Payable 9.2m
Accrued Liabilities 25.3m
Other Current Liabilities 74.7m
Non-Current Liabilities 50.5m
Long-Term Debt 4m
Other Non-Current Liabilities 46.6m
Efficiency

Earnings Waterfall
Standard BioTools Inc

Revenue
106.3m USD
Cost of Revenue
-55.9m USD
Gross Profit
50.5m USD
Operating Expenses
-113.5m USD
Operating Income
-63m USD
Other Expenses
-11.6m USD
Net Income
-74.7m USD

Free Cash Flow Analysis
Standard BioTools Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

LAB Profitability Score
Profitability Due Diligence

Standard BioTools Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
ROE is Increasing
Positive 1-Year Revenue Growth
24/100
Profitability
Score

Standard BioTools Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

LAB Solvency Score
Solvency Due Diligence

Standard BioTools Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Short-Term Solvency
46/100
Solvency
Score

Standard BioTools Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

LAB Price Targets Summary
Standard BioTools Inc

Wall Street analysts forecast LAB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LAB is 3.65 USD with a low forecast of 3.28 USD and a high forecast of 4.2 USD.

Lowest
Price Target
3.28 USD
39% Upside
Average
Price Target
3.65 USD
55% Upside
Highest
Price Target
4.2 USD
78% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

LAB Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

LAB Price
Standard BioTools Inc

1M 1M
-11%
6M 6M
+19%
1Y 1Y
+43%
3Y 3Y
-52%
5Y 5Y
-83%
10Y 10Y
-93%
Annual Price Range
2.36
52w Low
1.47
52w High
3.05
Price Metrics
Average Annual Return -25.54%
Standard Deviation of Annual Returns 69.76%
Max Drawdown -93%
Shares Statistics
Market Capitalization 902.6m USD
Shares Outstanding 382 460 992
Percentage of Shares Shorted 2.8%

LAB Return Decomposition
Main factors of price return

What is price return decomposition?

LAB News

Other Videos

Company Profile

Standard BioTools Inc Logo
Standard BioTools Inc

Country

United States of America

Industry

Life Sciences Tools & Services

Market Cap

902.6m USD

Dividend Yield

0%

Description

Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.

Contact

CALIFORNIA
South San Francisco
2 Tower Place, Suite 2000
+16502666000.0
https://www.fluidigm.com/

IPO

2011-02-10

Employees

615

Officers

President, CEO & Director
Dr. Michael Egholm Ph.D.
Chief Operating Officer
Mr. Hanjoon Kim
Chief Financial Officer
Mr. Jeffrey G. Black
Chief Technology Officer
Dr. Shane Bowen Ph.D.
Chief Strategy Officer
Mr. Adam Taich

See Also

Discover More
What is the Intrinsic Value of one LAB stock?

The intrinsic value of one LAB stock under the Base Case scenario is 3.84 USD.

Is LAB stock undervalued or overvalued?

Compared to the current market price of 2.36 USD, Standard BioTools Inc is Undervalued by 39%.